EB
EBS
Emergent BioSolutions Inc.
$8.24
+1.10%
$420.5M
No data for this timeframe.
Vol
Market Cap$420.5M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders8 funds
Inst. Value$92.7M
Inst. Activity3 buys / 1 sells
Insider Activity0B / 5S
Insider Net $-$525.2K
Reddit Sentiment43° Neutral
SEC Reports9
Press Releases4
Recent Activity
May 20, 2026
other
Emergent BioSolutions to Participate in Upcoming Investor Conferences
<p>GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) anno
May 4, 2026
SEC
Three directors of Emergent BioSolutions sold a total of approximately $385K in open-market shares over two days, repres
CLUSTER — Impact 2/10
May 1, 2026
Insider
Zoon Kathryn C sold 16,145 shares
Director @ $8.36 ($135.0K)
May 1, 2026
Insider
DeGolyer Donald W sold 14,527 shares
Director @ $8.36 ($121.4K)
May 1, 2026
Insider
Dayal Sujata Tyagi sold 12,781 shares
Director @ $8.36 ($106.8K)
Apr 30, 2026
SEC
Emergent BioSolutions reported Q1 2026 revenue of $156.1M (above the high-end of guidance) but GAAP EPS of $0.07 missed
PRESS-RELEASE — Impact 6/10
Apr 28, 2026
SEC
Emergent BioSolutions filed a DEFA14A (additional definitive proxy soliciting materials) on April 28, 2026, consisting o
DEFA14A — Impact 2/10
Inst.
MORGAN STANLEY — DOUBLED
1,157,696 shares ($14.3M)
Price Targets
$12.00
+45.6% upside
Strong Buy
Current $8.24
Low $12.00
Median $12.00
High $12.00
2 analysts
$12.00
$12.00
Analyst Ratings
1Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Dec 16, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.11 | $0.11 — $0.11 | -31% YoY | 1 |
| Next Q | $0.35 ▲ +40.0% | $0.35 — $0.35 | -67% YoY | 1 |
| Current FY | $0.95 ▲ +82.7% | $0.95 — $0.95 | -38% YoY | 1 |
| Next FY | $0.91 ▲ +295.7% | $0.91 — $0.91 | 398% YoY | 1 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Three directors of Emergent BioSolutions sold a total of approximately $385K in open-market shares over two days, repres
May 4, 2026
MIXED
PRESS-RELEASE
6/10
Emergent BioSolutions reported Q1 2026 revenue of $156.1M (above the high-end of guidance) but GAAP EPS of $0.07 missed
Apr 30, 2026
BULLISH
Press
4/10
Emergent BioSolutions announced a multi-year agreement with SAB Biotherapeutics to provide manufacturing services for SA
Apr 29, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $43.9M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $20.0M | ADD |
| MORGAN STANLEY | $14.3M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $7.1M | ADD |
| TWO SIGMA INVESTMENTS, LP | $3.2M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | Zoon Kathryn | SELL | $135.0K |
| May 1, 2026 | DeGolyer Donald | SELL | $121.4K |
| May 1, 2026 | Dayal Sujata | SELL | $106.8K |
| Apr 30, 2026 | Harsanyi Zsolt | A | $0.00 |
| Apr 30, 2026 | Harsanyi Zsolt | A | $0.00 |
Reddit Sentiment
43°
Neutral
Bearish
Neutral
Bullish
8 institutional holders with $92.7M total value (7,500,711 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, MORGAN. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,553,999 | $43.9M | 47.4% | — |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,618,903 | $20.0M | 21.6% | ADD +25.0% |
| 3 | MORGAN STANLEY | 1,157,696 | $14.3M | 15.4% | DOUBLED +118.9% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 577,147 | $7.1M | 7.7% | ADD +26.8% |
| 5 | TWO SIGMA INVESTMENTS, LP | 258,500 | $3.2M | 3.4% | TRIM -26.1% |
| 6 | BANK OF AMERICA CORP /DE/ | 146,944 | $1.8M | 2.0% | ADD +64.2% |
| 7 | FMR LLC | 118,311 | $1.5M | 1.6% | TRIM -37.1% |
| 8 | WELLS FARGO & COMPANY/MN | 69,211 | $855.4K | 0.9% | ADD +32.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 528,875 | 1,157,696 | +118.9% | $14.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 89,502 | 146,944 | +64.2% | $1.8M | 2025-Q4 |
| FMR LLC | TRIM | 188,174 | 118,311 | -37.1% | $1.5M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 52,104 | 69,211 | +32.8% | $855.4K | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,105,184 | 1,381,750 | +25.0% | $12.2M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 733,380 | 528,875 | -27.9% | $4.7M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 353,669 | 261,331 | -26.1% | $2.3M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 309,947 | 89,502 | -71.1% | $789.4K | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 583,271 | 1,105,184 | +89.5% | $7.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 93,317 | 309,947 | +232.1% | $2.0M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 11,076 | 45,691 | +312.5% | $291.5K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 1,226,985 | 866,467 | -29.4% | $4.2M | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 1,290,230 | 583,271 | -54.8% | $2.8M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 846,766 | 396,800 | -53.1% | $1.9M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 8,347 | 11,076 | +32.7% | $53.8K | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 2,224,727 | 1,290,230 | -42.0% | $12.3M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 524,947 | 665,847 | +26.8% | $6.4M | 2024-Q4 |
| UBS Group AG | DOUBLED | 268,438 | 590,221 | +119.9% | $5.6M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 20,012 | 8,347 | -58.3% | $79.8K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 2,224,727 | — | $18.6M | 2024-Q3 |
16 unique insiders with 5 transactions. Net insider value: -$525.2K ($0.00 bought, $525.2K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | Zoon Kathryn C | Director | SELL | 16,145 | $8.36 | $135.0K |
| May 1, 2026 | DeGolyer Donald W | Director | SELL | 14,527 | $8.36 | $121.4K |
| May 1, 2026 | Dayal Sujata Tyagi | Director | SELL | 12,781 | $8.36 | $106.8K |
| Apr 30, 2026 | Harsanyi Zsolt | Chairman | A | 25,344 | $0.00 | $0.00 |
| Apr 30, 2026 | Harsanyi Zsolt | Chairman | A | 11,296 | $0.00 | $0.00 |
| Apr 30, 2026 | Fowler Neal Franklin | Director | A | 25,344 | $0.00 | $0.00 |
| Apr 30, 2026 | Fowler Neal Franklin | Director | A | 11,296 | $0.00 | $0.00 |
| Apr 30, 2026 | Zoon Kathryn C | Director | A | 25,344 | $0.00 | $0.00 |
| Apr 30, 2026 | Zoon Kathryn C | Director | A | 11,296 | $0.00 | $0.00 |
| Apr 30, 2026 | Richard Ronald | Director | A | 25,344 | $0.00 | $0.00 |
| Apr 30, 2026 | Richard Ronald | Director | A | 11,296 | $0.00 | $0.00 |
| Apr 30, 2026 | FOWLER JOHN D JR | Director | A | 25,344 | $0.00 | $0.00 |
| Apr 30, 2026 | FOWLER JOHN D JR | Director | A | 11,296 | $0.00 | $0.00 |
| Apr 30, 2026 | White Marvin L | Director | A | 11,296 | $0.00 | $0.00 |
| Apr 30, 2026 | White Marvin L | Director | A | 25,344 | $0.00 | $0.00 |
| Apr 30, 2026 | Katkin Keith | Director | A | 25,344 | $0.00 | $0.00 |
| Apr 30, 2026 | Katkin Keith | Director | SELL | 15,481 | $8.28 | $128.2K |
| Apr 30, 2026 | Katkin Keith | Director | A | 11,296 | $0.00 | $0.00 |
| Apr 30, 2026 | DeGolyer Donald W | Director | A | 25,344 | $0.00 | $0.00 |
| Apr 30, 2026 | DeGolyer Donald W | Director | A | 11,296 | $0.00 | $0.00 |
| Apr 30, 2026 | Dayal Sujata Tyagi | Director | A | 25,344 | $0.00 | $0.00 |
| Apr 30, 2026 | Dayal Sujata Tyagi | Director | A | 11,296 | $0.00 | $0.00 |
| Apr 29, 2026 | PAPA JOSEPH C | President and CEO | A | 187,708 | $0.00 | $0.00 |
| Apr 29, 2026 | Hartzel William | SVP, Bioservices | A | 100,111 | $0.00 | $0.00 |
| Apr 29, 2026 | Perl Jessica | SVP, General Counsel, Corp Sec | A | 104,282 | $0.00 | $0.00 |
| Apr 29, 2026 | LINDAHL RICHARD S | EVP, Chief Financial Officer | A | 162,680 | $0.00 | $0.00 |
| Apr 29, 2026 | Glessner Coleen | EVP, Quality & Ethics, and CPL | A | 100,111 | $0.00 | $0.00 |
| Apr 29, 2026 | Lowry Simon C | SVP, R&D, CMO | A | 100,111 | $0.00 | $0.00 |
| Apr 29, 2026 | Williams Paul Anthony | SVP, Products Business | A | 100,111 | $0.00 | $0.00 |
| Apr 1, 2026 | Williams Paul Anthony | SVP, Products Business | SELL | 4,000 | $8.44 | $33.8K |
| Mar 5, 2026 | Lowry Simon C | SVP, R&D, CMO | F | 10,636 | $8.44 | $89.8K |
| Mar 5, 2026 | Hartzel William | SVP, Bioservices | F | 9,493 | $8.44 | $80.1K |
| Mar 5, 2026 | PAPA JOSEPH C | President and CEO | F | 37,055 | $8.44 | $312.7K |
| Mar 5, 2026 | Glessner Coleen | EVP, Quality & Ethics, and CPL | F | 8,199 | $8.44 | $69.2K |
| Mar 5, 2026 | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | 23,650 | $8.44 | $199.6K |
| Mar 5, 2026 | Perl Jessica | SVP, General Counsel, Corp Sec | F | 6,465 | $8.44 | $54.6K |
| Mar 5, 2026 | Williams Paul Anthony | SVP, Products Business | F | 9,397 | $8.44 | $79.3K |
| Mar 3, 2026 | Lowry Simon C | SVP, R&D, CMO | A | 44,834 | $0.00 | $0.00 |
| Mar 3, 2026 | Perl Jessica | SVP, General Counsel, Corp Sec | A | 46,702 | $0.00 | $0.00 |
| Mar 3, 2026 | Williams Paul Anthony | SVP, Products Business | A | 44,834 | $0.00 | $0.00 |
| Mar 3, 2026 | Glessner Coleen | EVP, Quality & Ethics, and CPL | A | 44,834 | $0.00 | $0.00 |
| Mar 3, 2026 | LINDAHL RICHARD S | EVP, Chief Financial Officer | A | 72,856 | $0.00 | $0.00 |
| Mar 3, 2026 | PAPA JOSEPH C | President and CEO | A | 252,194 | $0.00 | $0.00 |
| Mar 3, 2026 | FOWLER JOHN D JR | Director | A | 5,006 | $8.99 | $45.0K |
| Mar 3, 2026 | Hartzel William | SVP, Bioservices | A | 44,834 | $0.00 | $0.00 |
| Mar 1, 2026 | LINDAHL RICHARD S | EVP, Chief Financial Officer | F | 683 | $8.15 | $5.6K |
| Feb 25, 2026 | LINDAHL RICHARD S | EVP, Chief Financial Officer | H | 20,321 | $0.00 | $0.00 |
| Feb 9, 2026 | Perl Jessica | SVP, General Counsel, Corp Sec | F | 918 | $11.03 | $10.1K |
| Feb 6, 2026 | Hartzel William | SVP, Bioservices | D | 5,771 | $10.92 | $63.0K |
| Feb 6, 2026 | Hartzel William | SVP, Bioservices | F | 630 | $10.92 | $6.9K |
9 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 7 neutral. Avg impact: 3.2/10.
NEUTRAL
CLUSTER
2/10
Three directors of Emergent BioSolutions sold a total of approximately $385K in open-market shares o
May 4, 2026
MIXED
PRESS-RELEASE
6/10
Emergent BioSolutions reported Q1 2026 revenue of $156.1M (above the high-end of guidance) but GAAP
Apr 30, 2026
NEUTRAL
DEFA14A
2/10
Emergent BioSolutions filed a DEFA14A (additional definitive proxy soliciting materials) on April 28
Apr 28, 2026
NEUTRAL
DEFA14A
2/10
Emergent BioSolutions filed a DEFA14A announcing its virtual annual meeting of stockholders on April
Apr 27, 2026
BEARISH
PRESS-RELEASE
7/10
Emergent BioSolutions announced a $150 million term loan refinancing with OrbiMed and an amended $50
Apr 16, 2026
NEUTRAL
PRESS-RELEASE
3/10
Emergent BioSolutions announced a future earnings call for Q1 2026 but did not release actual financ
Apr 16, 2026
NEUTRAL
DEFA14A
3/10
Emergent BioSolutions Inc. (EBS) filed its definitive proxy statement (DEFA14A) for its 2026 Annual
Apr 16, 2026
NEUTRAL
DEFA14A
3/10
Emergent BioSolutions Inc. filed its definitive proxy statement for the 2026 annual shareholder meet
Apr 16, 2026
NEUTRAL
DEFA14A
1/10
Analysis based on filing metadata only — document content was unavailable
Mar 20, 2026
BULLISH
4/10
Emergent BioSolutions announced a multi-year agreement with SAB Biotherapeutics to provide manufactu
Apr 29, 2026
NEUTRAL
1/10
Emergent BioSolutions announced a partnership with baseball player Davis Schneider to promote awaren
Apr 29, 2026
NEUTRAL
4/10
Emergent BioSolutions announced a ~$34.5M agreement with Substipharm Biologics to manufacture drug s
Apr 28, 2026
BULLISH
7/10
Emergent BioSolutions announced a $54 million contract extension with the U.S. government for VIGIV,
Mar 25, 2026
Current analyst consensus: Strong Buy (83% buy). Based on 6 analysts: 1 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$12.00 mean target
+45.6% upside
Strong Buy (3.00)
$12.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $8.24 |
| Target Low | $12.00 |
| Target Mean | $12.00 |
| Target Median | $12.00 |
| Target High | $12.00 |
| # Analysts | 2 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.11 | $0.11 | $0.11 | -31.3% | +0.0% | — | $0.2B | 26.0% | 1 |
| Next Q 2026-09-30 |
$0.35 | $0.35 | $0.35 | -67.0% | +40.0% | 1↑ 0↓ | $0.2B | -9.6% | 1 |
| Current FY 2026-12-31 |
$0.95 | $0.95 | $0.95 | -37.9% | +82.7% | 1↑ 0↓ | $0.7B | -1.3% | 1 |
| Next FY 2027-12-31 |
$0.91 | $0.91 | $0.91 | 398.4% | +295.7% | 1↑ 0↓ | $0.9B | 21.7% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.110 | |
| 7d ago | $0.110 | |
| 30d ago | $0.110 | |
| 60d ago | $0.110 | |
| 90d ago | $0.000 | +0.110 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Apr 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Mar 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Feb 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Jan 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
43°
Neutral
Bearish
Neutral
Bullish
3 mentions
1 bullish
2 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 14, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 14, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 8, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Connecticut's first case of clade I mpox + ANDV virus
▲ 1
💬 0
⚡ 0.5
Hantavirus portfolio
▲ 1
💬 0
⚡ 0.4
May 20, 2026
other
Emergent BioSolutions to Participate in Upcoming Investor Conferences
<p>GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior m
May 18, 2026
other
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
<p align="left">GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced t
May 6, 2026
Clinical Trial
VELOCITY: An Anthrax Vaccine Clinical Study
Phase Phase 3 — COMPLETED
May 5, 2026
short_volume
Short Volume: EBS — 55.6% short (0.3M / 0.6M)
Short: 321,574 | Exempt: 13,342 | TRF Vol: 578,164 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_volume
Short Volume: EBS — 67.1% short (0.4M / 0.6M)
Short: 411,880 | Exempt: 833 | TRF Vol: 613,586 | Short Ratio: 67.1% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings
Emergent BioSolutions Reports First Quarter 2026 Financial Results
<p align="justify">GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for
Apr 30, 2026
other
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
<p>GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore’s Health Sciences Aut
Apr 30, 2026
earnings_calendar
EBS Q1 2026 Earnings Scheduled — 2026-04-30
Apr 29, 2026
contract
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
<p>GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Bio
Apr 29, 2026
contract
Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives
<p>WINNIPEG, Manitoba, April 29, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced it is teaming up with professional base
Apr 28, 2026
contract
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
<p>GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an ag
Apr 16, 2026
earnings
Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
Refinancing extends maturities, reduces interest expense and positions Emergent for durable, long-term growth as part of its multi-year transformation
Apr 16, 2026
earnings
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
<p align="left">GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday
Apr 9, 2026
contract
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program
<p>WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Prov
Apr 7, 2026
other
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
New product offerings and educational initiative, Ready to Rescue, aim to increase access and adoption of NARCAN® Nasal Spray to empower communities t
Mar 25, 2026
contract
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
<p>GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valu